News

The arrangement enables Sentynl to acquire exclusive US commercial rights to alvelestat upon exercise of the option while Mereo BioPharma will retain commercial rights outside the US. Under

The transaction is structured through a share purchase agreement with SEVER Life Sciences for 100% of Nordic Group and its subsidiaries. While specific financial terms have not been

The deal includes joint studies combining BeOne’s cancer pipeline assets with four clinical-stage RAS(ON) inhibitors from Revolution Medicines, alongside a regional rights agreement for select Asian markets. The

Unanimously approved by both companies’ boards, the transaction is expected to close by the fourth quarter (Q4) of 2026, pending customary closing conditions. Jazz Pharmaceuticals plans to fund

Under the contract, Daiichi Sankyo will continue to handle development, manufacturing, and supply of the therapy while Innovent Biologics will lead market promotion and commercialisation activities in China.

The collaboration will focus on process technology transfer and activities relating to chemistry, manufacturing and controls (CMC) to support a possible new drug application (NDA) in Taiwan for

These conditions often result in organ failure due to myofibroblast activation, scarring, and tissue inflammation. Ono will work alongside Mediar to utilise its fibrosis-focused discovery platform, expertise in

This collaboration will focus on utilising Evotec’s data-driven discovery platform alongside its AI data science and advanced screening technologies. It aims to accelerate the discovery and validation of

The agreement involves access to ALT-B4 (berahyaluronidase alfa), a recombinant human hyaluronidase created with Alteogen’s Hybrozyme platform. This technology is intended to convert biologics typically given via intravenous